<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02530827</url>
  </required_header>
  <id_info>
    <org_study_id>CAAE 01848612.1.0000.5440</org_study_id>
    <nct_id>NCT02530827</nct_id>
  </id_info>
  <brief_title>Energy Expenditure of People Living With HIV/AIDS</brief_title>
  <official_title>Influence of Lipid-lowering Drugs in Patients Seropositive for HIV With Lipodystrophy in Resting Energy Expenditure and Total Energy Expenditure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Several studies have reported increased resting energy expenditure (REE) in
      people living with HIV/AIDS possibly due to changes in body composition that occurs in HIV
      lipodystrophy syndrome.

      The aim of this study was to evaluate the influence of the use of lipid-lowering drugs in
      resting energy expenditure (REE) and total energy expenditure (TEE) in patients seropositive
      for HIV in treatment of lipodystrophy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      REE was measured by indirect calorimetry.

      TEE was measured by doubly labeled water (DLW) technique and an activity monitor based on
      accelerometry (AM).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total Energy Expenditure (kcal/d)</measure>
    <time_frame>14 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Resting Energy Expenditure (kcal/d)</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between doubly labeled water and accelerometer to measure total energy expenditure (ICC, 95% CI)</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">45</enrollment>
  <condition>HIV/AIDS</condition>
  <condition>HIV Lipodystrophy Syndrome</condition>
  <arm_group>
    <arm_group_label>LIPO-HIPO-</arm_group_label>
    <description>HIV-seropositive without lipodystrophy and no use of lipid-lowering drugs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIPO+HIPO-</arm_group_label>
    <description>HIV-seropositive with lipodystrophy and no use of lipid-lowering drugs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIPO+HIPO+</arm_group_label>
    <description>HIV-seropositive with lipodystrophy and use of lipid-lowering drugs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>use of lipid-lowering drugs.</intervention_name>
    <description>The patients shoud be in use of a lipid-lowering drugs previouly, at least one month before of the begining of the study.</description>
    <arm_group_label>LIPO+HIPO+</arm_group_label>
    <other_name>statins and fibrates</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      urine.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Men previously diagnosed with HIV infection, on antiretroviral therapy.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Use of antiretroviral therapy for at least 4 months

          -  A cluster of differentiation 4 (CD4) T-cell count of &gt;200 cells/mm3

          -  Use of lipid-lowering drugs for at least 1 month (group HIV-seropositive with
             lipodystrophy and use of lipid-lowering)

        Exclusion Criteria:

          -  Signs or symptoms of opportunistic infections

          -  Thyroid disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2015</study_first_submitted>
  <study_first_submitted_qc>August 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2015</study_first_posted>
  <last_update_submitted>August 20, 2015</last_update_submitted>
  <last_update_submitted_qc>August 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>energy expenditure</keyword>
  <keyword>doubly labeled water</keyword>
  <keyword>accelerometer</keyword>
  <keyword>HIV</keyword>
  <keyword>lipodystrophy syndrome.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lipodystrophy</mesh_term>
    <mesh_term>HIV-Associated Lipodystrophy Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypolipidemic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

